Welcome to our dedicated page for Check Cap news (Ticker: CHEKZ), a resource for investors and traders seeking the latest updates and insights on Check Cap stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Check Cap's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Check Cap's position in the market.
Check-Cap Ltd. (NASDAQ: CHEK, CHEKZ) announced financial results for Q4 and the full year ended December 31, 2022. The company reported a net loss of $3.7 million for Q4 2022, down from $5.5 million in Q4 2021. R&D expenses for the year rose to $14.3 million from $12.3 million, while general and administrative expenses increased to $5.8 million compared to $5.0 million in 2021. The company’s cash position at year-end was $42.1 million, which is projected to fund operations into Q4 2024. However, the initiation of the powered portion of its pivotal U.S. study is postponed as current efficacy results do not meet the required goals.
